Stock Trading Ideas

Trading Ideas Recent News

Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves 'Room For Altcoins To Pick Up'
Bitcoin moved sideways while the altcoin market rallied significantly on Monday as traders pivoted away from the leading cryptocurrency ahead of Christmas.
Druckenmiller Bets Big On Semiconductor Stock Just Before It Spikes To $1 Trillion
Billionaire investor Stanley Druckenmiller upped his stake in Broadcom Inc, known for his top-down investing style and focus on macro trends.
Investors Following Housing Sentiment May Consider Direxion's NAIL ETF
Sponsored
Meta User Base, AI-Powered Ad Growth Drive Analyst Optimism
Rosenblatt analyst maintains Buy rating on Meta Platforms Inc with $811 price target. Impressive AI-driven growth expected to continue.
Gold Moves Lower, Rumble Shares Jump
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
5 Tech Stocks to Buy as AI Hype Fizzles
Fed chair Powell dropped a big lump of coal in the market’s stocking last week as he reigned in the Fed’s rate cut projections for 2025. While the Fed cut its key benchmark rate by the expected 25 basis points, Powell tempered expectations on future rate cuts based on sticky inflation data and the continued robust spending from American consumers.
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.
Your Christmas Roadmap to the Market's Most Hidden Profits
Happy Holidays! Explore community bank stocks for investing success. Charlie Munger hinted at it. Learn why consolidation creates opportunities.
Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November
Market Clubhouse Morning Memo - December 23rd, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META and TSLA)
Bullish Technical Signal, Santa Claus Rally, Taking Advantage Of Hopium
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients.
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved